IL-17 Triggers Invasive and Migratory Properties in Human MSCs, while IFNy Favors their Immunosuppressive Capabilities: Implications for the “Licensing” Process

Mesenchymal stromal cells (MSCs) were first used as a source for cell therapy in 1995; however, despite their versatility and unambiguous demonstration of efficacy and safety in preclinical/phase I studies, the positive effect of MSCs in human phase III studies did not resemble the success obtained...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stem Cell Rev Rep
Hauptverfasser: Du-Rocher, Bárbara, Binato, Renata, de-Freitas-Junior, Julio Cesar Madureira, Corrêa, Stephany, Mencalha, André Luiz, Morgado-Díaz, José Andrés, Abdelhay, Eliana
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7667142/
https://ncbi.nlm.nih.gov/pubmed/33067729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12015-020-10051-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge